View Author
patient interferon melanoma group survival treatment cancer observation study lymph number density hospital interferon group observation group recurrence-free survival metastasis-free survival pegylated analysis trial event center stage recurrence-free dendritic cells disease dendritic e ffect lymph nodes dc-lamp death research adjuvant article ulceration response eortc table sentinel university metastasis-free thickness sentinel lymph nodes category prognostic nodal hazard ratio centre tumour tumor dcdc-lamp phase randomisation metastasi month involvement toxicity analyses cancer research duration value recurrence randomised stage iii melanoma metastase maturation nodal disease p value adjuvant therapy association therapy nodal involvement grade univariate signi dc density follow-up prognostic importance micrometastatic
2 Most Recent Publications
|
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
(Article)
Eggermont, A.M.M. Suciu, S. Kusic, Z. Dummer, R. Hauschild, A. Musat, E. Spatz, A. Keilholz, U. Santinami, M. Testori, A. Kruit, W.H.J. Marsden, J. Punt, C.J.A. Salès, F. Gore, M. MacKie, R.M. |
2008-07-14
|
|
Long-term protective effect of mature DC-LAMP
+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma
(Article)
Elliott, B. Scolyer, R.A. Testori, A. Eggermont, A.M.M. MacKie, R.M. Robert, C. Cook, M. Thompson, J.F. Angevin, E. Spatz, A. Suciu, S. Lebecque, S. Rimoldi, D. Gugerli, O. Musat, E. Sharma, R.N. Lienard, D. Keilholz, U. |
2007-07-01
|